GlassScriptPhysician profile
Richard P Ward
NPI 1619996071
$2,476.03
in general payments reported to CMS, 2019-2025
28 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,239 · 2020: $185 · 2021: $265 · 2022: $225 · 2023: $228 · 2024: $153 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $561.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $411.39 | 2019-2024 | |
| Novo Nordisk INC | $308.94 | 2019-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $283.20 | 2019-2025 | Shingrix, Arexvy |
| Abbott Laboratories | $247.78 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $209.22 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.07 | 2019-2022 | |
| Amarin Pharma, INC. | $105.64 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.29 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $67.43 | 2019-2022 | |
| Amgen INC. | $64.99 | 2019-2023 | Repatha |
| Mylan Specialty L.P. | $61.78 | 2019-2020 | |
| Astellas Pharma US INC | $61.39 | 2021-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $48.53 | 2019 | |
| Lilly USA, LLC | $46.41 | 2019 | |
| Insulet Corporation | $35.08 | 2019-2023 | Omnipod |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $34.41 | 2022 | |
| Corcept Therapeutics | $30.85 | 2019 | |
| Merck Sharp & Dohme LLC | $29.99 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.38 | 2019 | |
| Abbvie INC. | $17.12 | 2023 | Vraylar |
| Biogen, INC. | $16.41 | 2021 | |
| Valeritas, INC. | $16.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.44 | 2022 | |
| Exact Sciences Corporation | $14.14 | 2023 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $13.65 | 2022 | |
| Sanofi Pasteur INC. | $12.95 | 2020 | |
| Dynavax Technologies Corporation | $12.05 | 2024-2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.